Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland
Abstract Advances in biologic and targeted synthetic DMARDs have expanded treatment options for spondylarthritis. Despite improvements with TNF inhibitors, many patients remain refractory. Secukinumab, an IL-17A inhibitor, has shown promise in controlled trials. This study evaluates its real-world r...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-11070-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!